7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
May 2025 in “Reactions Weekly” July 2024 in “Reactions Weekly”
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
19 citations
,
February 2007 in “International Clinical Psychopharmacology” Quetiapine may cause hair loss, a side effect not widely recognized before.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
8 citations
,
January 2016 in “Case Reports in Psychiatry” Trichotillomania in dementia may be better treated with dopamine blockers like quetiapine than with SSRIs.
Baricitinib works better than methotrexate for severe alopecia areata.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
May 2024 in “Reactions weekly”
4 citations
,
August 2021 in “Biomedicine & Pharmacotherapy” 5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.
3 citations
,
February 2014 in “Anadolu psikiyatri dergisi” A teenager's hair loss was caused by the drug quetiapine but improved after stopping the medication.
November 2023 in “Children” Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
March 2025 in “Biomedical & Pharmacology Journal” Valproic acid is effective but often causes side effects like weight gain and hair loss, so personalized treatment is needed.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.